The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Opioid Induced Constipation (OIC) Drug Market Research Report 2025
Synopsis
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation (OIC) Drug market was valued at US$ 2531 million in 2023 and is anticipated to reach US$ 3490.4 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Opioid Induced Constipation (OIC) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid Induced Constipation (OIC) Drug.
Report Scope
The Opioid Induced Constipation (OIC) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Opioid Induced Constipation (OIC) Drug market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid Induced Constipation (OIC) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation (OIC) Drug market was valued at US$ 2531 million in 2023 and is anticipated to reach US$ 3490.4 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Opioid Induced Constipation (OIC) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid Induced Constipation (OIC) Drug.
Report Scope
The Opioid Induced Constipation (OIC) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Opioid Induced Constipation (OIC) Drug market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid Induced Constipation (OIC) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Opioid Induced Constipation (OIC) Drug Market Overview
1.1 Product Overview and Scope of Opioid Induced Constipation (OIC) Drug
1.2 Opioid Induced Constipation (OIC) Drug Segment by Type
1.2.1 Global Opioid Induced Constipation (OIC) Drug Market Value Comparison by Type (2024-2030)
1.2.2 Lubiprostone
1.2.3 Methyl Naltrexone Bromide
1.2.4 Naldemedine
1.2.5 Alvimopan
1.2.6 Other
1.3 Opioid Induced Constipation (OIC) Drug Segment by Distribution Channel
1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Value by Distribution Channel: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Opioid Induced Constipation (OIC) Drug Market Size Estimates and Forecasts
1.4.1 Global Opioid Induced Constipation (OIC) Drug Revenue 2019-2030
1.4.2 Global Opioid Induced Constipation (OIC) Drug Sales 2019-2030
1.4.3 Global Opioid Induced Constipation (OIC) Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Opioid Induced Constipation (OIC) Drug Market Competition by Manufacturers
2.1 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Opioid Induced Constipation (OIC) Drug Average Price by Manufacturers (2019-2024)
2.4 Global Opioid Induced Constipation (OIC) Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Opioid Induced Constipation (OIC) Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Opioid Induced Constipation (OIC) Drug, Product Type & Application
2.7 Opioid Induced Constipation (OIC) Drug Market Competitive Situation and Trends
2.7.1 Opioid Induced Constipation (OIC) Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Opioid Induced Constipation (OIC) Drug Players Market Share by Revenue
2.7.3 Global Opioid Induced Constipation (OIC) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Opioid Induced Constipation (OIC) Drug Retrospective Market Scenario by Region
3.1 Global Opioid Induced Constipation (OIC) Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Opioid Induced Constipation (OIC) Drug Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2019-2030
3.2.1 Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2019-2024
3.2.2 Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2025-2030
3.3 Global Opioid Induced Constipation (OIC) Drug Global Opioid Induced Constipation (OIC) Drug Revenue by Region: 2019-2030
3.3.1 Global Opioid Induced Constipation (OIC) Drug Revenue by Region: 2019-2024
3.3.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Region: 2025-2030
3.4 North America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Country
3.4.1 North America Opioid Induced Constipation (OIC) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Opioid Induced Constipation (OIC) Drug Sales by Country (2019-2030)
3.4.3 North America Opioid Induced Constipation (OIC) Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Country
3.5.1 Europe Opioid Induced Constipation (OIC) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2019-2030)
3.5.3 Europe Opioid Induced Constipation (OIC) Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Country
3.7.1 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2019-2030)
3.7.3 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Opioid Induced Constipation (OIC) Drug Sales by Type (2019-2030)
4.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Type (2019-2024)
4.1.2 Global Opioid Induced Constipation (OIC) Drug Sales by Type (2025-2030)
4.1.3 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Type (2019-2030)
4.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Type (2019-2030)
4.2.1 Global Opioid Induced Constipation (OIC) Drug Revenue by Type (2019-2024)
4.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Type (2025-2030)
4.2.3 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Type (2019-2030)
4.3 Global Opioid Induced Constipation (OIC) Drug Price by Type (2019-2030)
5 Segment by Distribution Channel
5.1 Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2019-2030)
5.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2019-2024)
5.1.2 Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2025-2030)
5.1.3 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Distribution Channel (2019-2030)
5.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Distribution Channel (2019-2030)
5.2.1 Global Opioid Induced Constipation (OIC) Drug Revenue by Distribution Channel (2019-2024)
5.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Distribution Channel (2025-2030)
5.2.3 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Distribution Channel (2019-2030)
5.3 Global Opioid Induced Constipation (OIC) Drug Price by Distribution Channel (2019-2030)
6 Key Companies Profiled
6.1 Ironwood Pharmaceuticals
6.1.1 Ironwood Pharmaceuticals Corporation Information
6.1.2 Ironwood Pharmaceuticals Description and Business Overview
6.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
6.1.5 Ironwood Pharmaceuticals Recent Developments/Updates
6.2 Daiichi Sankyo Co
6.2.1 Daiichi Sankyo Co Corporation Information
6.2.2 Daiichi Sankyo Co Description and Business Overview
6.2.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Portfolio
6.2.5 Daiichi Sankyo Co Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Progenics Pharmaceuticals
6.4.1 Progenics Pharmaceuticals Corporation Information
6.4.2 Progenics Pharmaceuticals Description and Business Overview
6.4.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
6.4.5 Progenics Pharmaceuticals Recent Developments/Updates
6.5 Shionogi &
6.5.1 Shionogi & Corporation Information
6.5.2 Shionogi & Description and Business Overview
6.5.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Product Portfolio
6.5.5 Shionogi & Recent Developments/Updates
6.6 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Allergan Opioid Induced Constipation (OIC) Drug Product Portfolio
6.6.5 Allergan Recent Developments/Updates
6.7 Nektar Therapeutics
6.6.1 Nektar Therapeutics Corporation Information
6.6.2 Nektar Therapeutics Description and Business Overview
6.6.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Portfolio
6.7.5 Nektar Therapeutics Recent Developments/Updates
6.8 Purdue Pharma
6.8.1 Purdue Pharma Corporation Information
6.8.2 Purdue Pharma Description and Business Overview
6.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
6.8.5 Purdue Pharma Recent Developments/Updates
6.9 S.L.A. Pharma
6.9.1 S.L.A. Pharma Corporation Information
6.9.2 S.L.A. Pharma Description and Business Overview
6.9.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
6.9.5 S.L.A. Pharma Recent Developments/Updates
6.10 Mundipharma International Limited
6.10.1 Mundipharma International Limited Corporation Information
6.10.2 Mundipharma International Limited Description and Business Overview
6.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
6.10.5 Mundipharma International Limited Recent Developments/Updates
6.11 Ono Pharmaceutical
6.11.1 Ono Pharmaceutical Corporation Information
6.11.2 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.11.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
6.11.5 Ono Pharmaceutical Recent Developments/Updates
6.12 Takeda Pharmaceutical Company Limited
6.12.1 Takeda Pharmaceutical Company Limited Corporation Information
6.12.2 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
6.12.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.13 Theravance Biopharma
6.13.1 Theravance Biopharma Corporation Information
6.13.2 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.13.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Portfolio
6.13.5 Theravance Biopharma Recent Developments/Updates
6.14 Bausch Health
6.14.1 Bausch Health Corporation Information
6.14.2 Bausch Health Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.14.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Bausch Health Opioid Induced Constipation (OIC) Drug Product Portfolio
6.14.5 Bausch Health Recent Developments/Updates
6.15 Cosmo Pharmaceuticals SA
6.15.1 Cosmo Pharmaceuticals SA Corporation Information
6.15.2 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Portfolio
6.15.5 Cosmo Pharmaceuticals SA Recent Developments/Updates
6.16 Daewoong Pharmaceutical
6.16.1 Daewoong Pharmaceutical Corporation Information
6.16.2 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
6.16.5 Daewoong Pharmaceutical Recent Developments/Updates
6.17 C.B. Fleet Company
6.17.1 C.B. Fleet Company Corporation Information
6.17.2 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Portfolio
6.17.5 C.B. Fleet Company Recent Developments/Updates
6.18 Sucampo Pharmaceuticals
6.18.1 Sucampo Pharmaceuticals Corporation Information
6.18.2 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Description and Business Overview
6.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
6.18.5 Sucampo Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opioid Induced Constipation (OIC) Drug Industry Chain Analysis
7.2 Opioid Induced Constipation (OIC) Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opioid Induced Constipation (OIC) Drug Production Mode & Process
7.4 Opioid Induced Constipation (OIC) Drug Sales and Marketing
7.4.1 Opioid Induced Constipation (OIC) Drug Sales Channels
7.4.2 Opioid Induced Constipation (OIC) Drug Distributors
7.5 Opioid Induced Constipation (OIC) Drug Customers
8 Opioid Induced Constipation (OIC) Drug Market Dynamics
8.1 Opioid Induced Constipation (OIC) Drug Industry Trends
8.2 Opioid Induced Constipation (OIC) Drug Market Drivers
8.3 Opioid Induced Constipation (OIC) Drug Market Challenges
8.4 Opioid Induced Constipation (OIC) Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
